| Document |
Document Title |
|
WO/2023/012182A1 |
The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of SAPHO syndrome in a subject in need thereof.
|
|
WO/2023/009424A1 |
The present invention relates to biodegradable agents associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) one or more of a therapeutic agent (e.g., configured for treating, preventing or ameliorating ...
|
|
WO/2023/008459A1 |
This medicament characterized by containing, together or separately in combination with a HDAC inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein is useful as a medicament for treatmen...
|
|
WO/2023/008470A1 |
The present invention provides a fused-ring amine derivative that has a DYRK inhibiting action and that is represented by formula (1) (refer to the description with respect to A1, L1, T, Z, and I in the formula), or a pharmaceutically ac...
|
|
WO/2023/008461A1 |
The present invention relates to a medicament for the treatment and/or prevention of cancer, the medicament being characterized by comprising an antibody having an immunological reactivity with CAPRIN-1 protein or a fragment of the antib...
|
|
WO/2023/009829A1 |
Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be er...
|
|
WO/2023/006745A1 |
The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of hypertension in a non-human mammal, preferably a carnivore, in particular ...
|
|
WO/2023/007088A1 |
The oral food supplement which makes it possible to protect against infertility caused by premature ovarian insufficiency or by endometriosis or by polycystic ovary syndrome (PCOS) in women, or by low sperm count in men, this being both ...
|
|
WO/2023/008472A1 |
The present invention provides a benzothiazole derivative represented by formula (I) (in the formula, A1, L and Q are as defined in the description) or a pharmaceutically acceptable salt thereof, which exhibits a DYRK inhibitory activity...
|
|
WO/2023/009710A1 |
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, either alone or in combination with o...
|
|
WO/2023/005959A1 |
Provided are new compositions and methods useful for the treatment, prevention, and potential cure of Alzheimer's Disease by disrupting the genomic locus of IL1LR1 gene including rs1921622 and/or other 574 sST2-associated genomic sites a...
|
|
WO/2023/008768A1 |
The present invention relates to a cosmetic composition and a pharmaceutical composition, which comprise, as an active ingredient, Recoflavone or a salt thereof, and thus have an antioxidant effect and the excellent effects of skin white...
|
|
WO/2023/008462A1 |
The present invention relates to a medicament for the treatment and/or prevention of cancer, the medicament being characterized by comprising an antibody having an immunological reactivity with CAPRIN-1 protein or a fragment of the antib...
|
|
WO/2023/008921A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, which contains an antiviral agent and an antidepressant as active ingredients, and to which a biguanide-based compound can be added. More pa...
|
|
WO/2023/007779A1 |
The present invention provides a pharmaceutical composition for treating peripheral nerve injury, said pharmaceutical composition comprising a substance that inhibits the formation of neutrophil extracellular traps (NETs) outside the par...
|
|
WO/2023/009330A1 |
The invention describes novel serotonin c5-HT2B receptor antagonists of Formula (1), and pharmaceutically acceptable salts thereof; wherein Ring A, L, X, X', R3, (1) R4, m and n are as defined herein. Also described are compositions comp...
|
|
WO/2023/008570A1 |
Provided herein is a pharmaceutical composition for treating cancer, the pharmaceutical composition containing: a folic acid-modified hydroxyalkylated cyclodextrin selected from the group consisting of folic acid-modified hydroxypropylcy...
|
|
WO/2023/008936A1 |
According to an aspect of the technology disclosed by the present application, the present invention relates to a pharmaceutical composition for preventing or treating a tumor, including a low-molecular kinase inhibitor which blocks the ...
|
|
WO/2023/006127A1 |
The present application relates to a use of GP73 as a treatment target and a diagnostic marker for non-obese non-alcoholic fatty liver disease. GP73 promotes the occurrence and acceleration progress of non-obese NAFLD, and the inhibition...
|
|
WO/2023/008451A1 |
The present invention relates to a method for treatment of and/or rehabilitation from pulmonary interstitial diseases, particularly pulmonary fibrosis, by keeping a human body (a patient or similar) in a fasting condition, as well as a s...
|
|
WO/2023/007247A1 |
The invention provides carbazole derivatives for the treatment of lipoma pain in tissues and organs, in particular treatment of lipoma pain in Dercum's Disease (DD) patients.
|
|
WO/2023/009439A1 |
Skin graft methods are provided. Aspects of the methods include applying a skin graft to a wound in combination with a mechanotransduction blocker, such as a pharmacological mechanotransduction blocker, e.g., a focal adhesion kinase inhi...
|
|
WO/2023/008533A1 |
The present invention provides a pharmaceutical composition that, with respect to pancreatic cancer and bile duct cancer, suppresses cell proliferation and has an anti-cancer effect. The present invention pertains to: a pharmaceutical co...
|
|
WO/2023/008498A1 |
The present invention provides a novel non-lamellar liquid crystal-forming composition. According to an aspect of the present invention, a non-lamellar liquid crystal-forming composition comprises a fatty acid ester and a phospholipid,...
|
|
WO/2023/007430A1 |
The invention relates to compounds of general formula (I): for use in the prevention and/or treatment of infectious diseases.
|
|
WO/2023/008337A1 |
An anti-HBV agent according to the present invention contains, as an active ingredient, a substance which binds to LIPG and inhibits the functions of LIPG. The inventors of the present application have found that LIPG is a factor that pl...
|
|
WO/2023/006954A1 |
It relates to a compound of formula (I), particularly asenapine, or a pharmaceutically acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically acc...
|
|
WO/2023/005486A1 |
Provided are an EBV composite antigen, a dendritic cell vaccine and the use thereof for preparing an EBV-related infectious disease drug, which belong to the technical field of biomedicine. A dendritic cell of a patient is stimulated in ...
|
|
WO/2023/002007A1 |
The present application refers to a compound of formula (I), or a pharmaceutically or veterinary acceptable salt thereof, for use in treating infections caused by enveloped viruses. Pharmaceutical or veterinary compositions of the compou...
|
|
WO/2023/004344A1 |
This disclosure provides methods for treating T cell-driven inflammatory disorders. The methods include administering to a subject a therapeutically effective amount of a butyrophilin- like 2 (Btnl2) agent capable of increasing a level o...
|
|
WO/2023/001724A1 |
The present invention is in the field of pharmaceuticals, functional food products or supplements, and medical foods or food for special medical purposes (FSMP). In particular, the present invention relates to a combination of (i) a keto...
|
|
WO/2023/002008A1 |
The present invention relates to a composition comprising THX-B and at least one pharmaceutically acceptable excipient for use in the treatment or prevention of cancer and/or metastasis and to prognostic and diagnostic methods comprising...
|
|
WO/2023/000689A1 |
Disclosed are a peripheral blood TCR marker for IgA nephropathy, a detection kit thereof, and an application thereof. The marker comprises at least one of the proteins the sequences of which are shown in SEQ ID NO. 1-100. The present inv...
|
|
WO/2023/003972A1 |
Described herein is a method of treating a cancer or tumor in an individual, the method comprising administering to the individual afflicted with the cancer or tumor an effective amount of: a) nanatinostat; b) a nucleoside analog; c) and...
|
|
WO/2023/000131A1 |
An antibody drug conjugate (ADC) loaded with double toxins: MMAF is connected in series with another drug unit by means of a cysteine binding site on an antibody, and the two can exhibit a significant synergistic effect, thus effectively...
|
|
WO/2023/002725A1 |
Biomarkers are provided that predict whether a human subject having a tumor is in need of a therapy comprising an angiogenesis inhibitor (e.g. lenvatinib or a pharmaceutically acceptable salt thereof, such as lenvatinib mesylate). The bi...
|
|
WO/2023/004437A1 |
The present invention features method and composition that can be used to facilitate intracellular delivery of DNA to a subject. The provided methods and compositions employ a nanoparticle for intracellular DNA delivery and a cytosolic D...
|
|
WO/2023/001880A1 |
The invention relates to a bilayer tablet comprising telmisartan in combination with indapamide. Pref- erably, the bilayer tablet provides immediate release of telmisartan and prolonged release of indapamide. The invention also provides ...
|
|
WO/2023/002399A1 |
The present disclosure relates to the field of pharmacy, particularly to an NLRP3 inhibitor for use in the treatment of osteoarthritis. The disclosure also relates to an NLRP3 inhibitor or a pharmaceutical combination comprising an NLRP3...
|
|
WO/2023/000282A1 |
The present invention belongs to the technical fields of biotechnology and medicine, and specifically relates to a circIKBKB inhibitor and the use of a circIKBKB detection reagent in a diagnosis, treatment and prognosis kit for breast ca...
|
|
WO/2023/002219A1 |
The present invention relates to treatments of hereditary angioedema (HAE) with a plasma kallikrein inhibitor and oral modified release pharmaceutical dosage forms comprising a plasma kallikrein inhibitor for use in these treatments.
|
|
WO/2023/001842A1 |
The invention relates to a combination of: - naringin and - stanols for use in the treatment or prevention of hypercholesterolemia. The invention also relates to compositions comprising the combination.
|
|
WO/2023/286694A1 |
There are said to be approximately five million people worldwide who suffer from inflammatory bowel diseases including ulcerative colitis and Crohn's disease, and the development of therapeutic agents is hoped for. In particular, the dev...
|
|
WO/2023/287111A1 |
The present invention relates to a micelle complex and a drug carrier. The present invention supports hydrophobic manganese oxide particles on micelles for stable in vivo protection, thereby enabling easy transfer to a tumor part. Furthe...
|
|
WO/2023/287159A1 |
The present invention relates to a composition for preventing or treating bone diseases containing nanovesicles derived from Dioscorea japonica Thunb. As the nanovesicles isolated from a natural product are nontoxic, and effectively act ...
|
|
WO/2023/286823A1 |
The present invention provides a pharmaceutical composition which contains: an LAT1 inhibitor, such as 5-phenyl-5-[4-(trifluoromethyl)phenoxy]pentan-1-amine or a 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid or a pharmaceutically accept...
|
|
WO/2023/284159A1 |
The present invention relates to the field of medicines. Disclosed are a compound containing a sulfamide structure, and a preparation method therefor and an application thereof, and a pharmaceutical composition and an application. The co...
|
|
WO/2023/288173A1 |
The present invention provides pharmaceutical compositions, for storage and administration, comprising an anti-human B7-H3 ("hB7-H3") antibody ("enoblituzumab") and buffering agents. The invention provides containers and kits comprising ...
|
|
WO/2023/284733A1 |
The present invention relates to the field of biomedicine, and provides a GITR/TGF-β dual-targeted fusion protein, a conjugate and pharmaceutical composition comprising same, and a use of the fusion protein or conjugate in the preparati...
|
|
WO/2023/285573A1 |
A probiotic composition comprising Bifidobacterium longum subsp. longum CECT 7894 is provided. The probiotic composition is useful in treating, preventing, or ameliorating an intestinal barrier dysfunction (e.g., increased intestinal per...
|
